Table 2.
Characteristics of patients on continuous MTX and on MTX hold
| Characteristics | MTX n=24 | MTX pause n=26 | P value |
| Age, mean (SD) | 63.13 (13.9) | 60.35 (11.0) | 0.439 |
| Female, n (%) | 19 (79) | 21 (81) | 0.795 |
| BMI mean, (SD) | 26.1 (3.9) | 25.31 (4.1) | 0.489 |
| Rheumatic diagnosis | 0.855 | ||
| Rheumatic arthritis, n (%) | 17 (71) | 19 (73) | |
| Psoriatic arthritis, n (%) | 4 (17) | 3 (12) | |
| Other, n (%)* | 3 (12) | 4 (15) | |
| Medication | 0.441 | ||
| MTX-mono, n (%) | 7 (29) | 8 (31) | |
| MTX-prednisolone, n (%) | 7 (29) | 5 (19) | |
| MTX-TNF-α-inhibitor, n (%) | 5 (21) | 6 (23) | |
| MTX-TNF-α-inhibitor-prednisolone, n (%) | 4 (17) | 2 (8) | |
| MTX-other, n (%)† | 1 (4) | 5 (19) | |
| MTX-dose in mg/week, mean (SD) | 13.44 (4.2) | 11.63 (4.0) | 0.128 |
| Prednisolone in mg/d, mean (SD) | 4.50 (4.3) | 3.25 (1.8) | 0.423 |
| 3.Vaccination | 0.647 | ||
| BNT162b2, n (%) | 19 (79) | 19 (73) | |
| mRNA-1273, n (%) | 5 (21) | 7 (27) | |
| MTX regimen | |||
| MTX-dose in mg/week, mean (SD) | 13.44 (4.2) | 11.63 (4.0) | 0.128 |
| Duration of hold (days), mean (SD) | / | 19.9 (7.7) | |
| Duration of hold before vaccine (days), mean (SD) | / | 7.6 (3.9) | |
| Duration of hold after vaccine (days), mean (SD) | / | 12.4 (7.1) |
*MTX: Takayasu arteritis, blistering dermatitis, systemic sclerosis; MTX pause: 2 × axial spondylarthritis (ankylosing spondylitis), dermatomyositis/polymyositis, polymyalgia rheumatica.
†MTX: IL-12/IL-23-inhibitor; MTX pause: 2 × leflunomide, prednisolone/immunglobulins, hydroxychloroquine, IL-17-inhibitor.
BMI, body mass index; MTX, methotrexate.